Medical Marketing and Media |
Lexicon developing type 1 diabetes treatment with Sanofi
Medical Marketing and Media Sotagliflozin's dual SGLT1 and SGLT2 inhibition may represent a novel treatment option for patients with type 1 diabetes. Based on clinical results to date, it could greatly reduce the daily burden on these individuals, says Dr. Paul Strumph, Lexicon's … |
More details can be found at www.diabeteshowto.com
Discussion
Comments are disallowed for this post.
Comments are closed.